You are here

Our science / Clinical Trials / Find a Trial / NCT00246571

Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

Back to Search Print Save as PDF Bookmark Trial

NCT00246571

Last updated on February 20, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Corona, California, 92879 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Recurrent or metastatic breast cancer

- Estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2) negative
status

- Prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease
setting

- Relapse following adjuvant chemotherapy within 6 months of last treatment and/or
received one or two chemotherapy regimens for advanced disease

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- More than two chemotherapy regimens for advanced disease

- Uncontrolled/symptomatic spread of cancer to the brain

NCT00246571
Pfizer
Completed
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Advanced or Recurrent Solid Tumors, Breast Neoplasms, Epithelial Ovarian Cancer, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
NCT01286987
All Genders
18+
Years
Multiple Sites
Triple Negative Breast Neoplasms
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
NCT02299635
Females
18+
Years
Multiple Sites
Breast Neoplasms
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
NCT00076024
Females
18+
Years
Multiple Sites
Breast Neoplasms
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
NCT02297438
Females
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now